Table 1 Clinical characteristics and disease activity of patients with and without residual disease activity
|  | Total group (n = 142) | Residual disease activity according to rheumatologist (n = 90) | No residual disease activity according to rheumatologist (n = 52) | Residual disease vs no residual disease P value |
|---|---|---|---|---|
Age mean (SD) | 53.0 (12.6) | 53.6 (6.3) | 51.9 (13.6) | 0.000 |
Male/female n/n | 92/60 | 53/37 | 33/19 | 0.865 |
Disease duration diagnosis mean (SD) | 10.3 (7.9) | 11.0 (9.2) | 10.1 (6.8) | 0.494 |
on treatment > 6 months, % | 93 | 86 | 94 | 0.618 |
Current only DMARD user n (%) | 110 (49) | 52 (58) | 23 (44) | 0.032 |
Current first TNF user n (%) | 32 (22) | 14 (16) | 18 (35) | Â |
Current > 1 TNF user n (%) | 35 (24) | 24 (27) | 11 (21) |  |
Swollen joints | 0 (0–0) | 0 (0–1) | 0 (0–0) | 0.000 |
SJC of 0, n (%) | 111 (77) | 63 (70) | 49 (94) | |
SJC of 1, n (%) | 10 (7) | 8 (9) | 2 (4) | |
SJC of 2, n (%) | 5 (3) | 5 (6) | 0 (0) | |
SJC of ≥ 3, n (%) | 15 (10) | 14 (16) | 1 (2) | |
Tender joints | 1 (0–2) | 1 (0–3) | 0 (0–0) | 0.000 |
TJC of 0, n (%) | 82 (57) | 36 (40) | 46 (88) | |
TJC of 1, n (%) | 21 (13) | 16 (18) | 5 (10) | |
TJC of 2, n (%) | 12 (13) | 12 (13) | 0 (-) | |
TJC of 3, n (%) | 25 (17) | 24 (27) | 1 (2) | |
Number of dactylitic digits | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.017 |
Dactylitis count of 1, n (%) | 8 (6) | 8 (9) | 0 (-) | |
Number of enthesitis points | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.001 |
Enthesitis count of 1, n (%) | 14 (10) | 14 (16) | 0 (-) | |
Enthesitis count of 2–4, n (%) | 2 (1) | 2 (2) | 0 (-) | |
VAS physician skin severity | 1 (0–2) | 1 (1–2.5) | 1 (0–1) | 0.000 |
VAS physician overall disease activity | 1 (1–3) | 2 (1–4) | 1 (0–1) | 0.000 |
VAS patient global disease activity | 2 (1–6) | 5 (2–7) | 1 (0–2) | 0.000 |
VAS pt pain | 2 (1–6) | 5 (2–7) | 1 (0–2) | 0.000 |
BASDAI | 2,65 (1–4.8) | 4.1 (2.5–5.9) | 0.9 (0.4–1.8) | 0.000 |
cDAPSA remission, n (%) | 45 (32) | 9 (10) | 36 (69) | 0.000 |
cDAPSA low disease activity, n (%) | 49 (35) | 34 (38) | 15 (29) | Â |
cDAPSA moderate disease activity, n (%) | 35 (25) | 35 (39) | 0 (-) | Â |
cDAPSA high disease activity, n (%) | 6 (4) | 6 (7) | 0 (-) | Â |
cDAPSA missing, n (%) | 7 (5) | 6 (7) | 1 (2) | Â |